Table 1.
The Trop2-targeted antibodies in development.
| Agent | Institution/Company | Classification | Binding Epitope | Phase | Reference |
|---|---|---|---|---|---|
| RS7 | Immunomedics, Glead Science | Antibody | RCPD (Q237-Q252) | Preclinical | (17) |
| PrE11 | Kyowa Hakko Kirin | Antibody | CRD (C34-K72) | Preclinical | (33, 34) |
| Trop2-IgG | Nanjing Medical University | Antibody | – | Preclinical | (35) |
| AR47A6.4.2 | ARIUS Research | Antibody | CPD (L179-H187 and Q252-Y260) | Preclinical | (36) |
| 77220, MOv16, MM0588-49D6, YY-01, 162-46.2, T16, E1 | Kyowa Hakko Kirin | Antibody | CPD (D146-R178) | Preclinical | (22, 33, 37) |
| 7E6 | Michigan State University | Antibody | CPD (D171, R178, and G241-P250) | Preclinical | (38) |
| TrMab-6 | Tohoku University | Antibody | – | Preclinical | (39) |
| TrMab-29 | Tohoku University | Antibody | – | Preclinical | (40) |
| K5-70 | Chiome Bioscience | Antibody | CRD (V43-D65) | Preclinical | – |
| hIMB1636 | Chinese Academy of Medical Sciences & Peking Union Medical College | Antibody | – | Preclinical | (41) |
| 2EF | University of Messina | Antibody | CRD or TY | Preclinical | (42) |
| 2G10 | University of Messina | Antibody | CPD | Preclinical | (43) |
| Trop2-Fab | Nanjing Medical University | Fab | – | Preclinical | (44) |
| (E1)-3s | Immunomedics | Bispecific antibody (Trop2/CD3) | RCPD (Q237-Q252) | Preclinical | (45) |
| F7AK3 | Huazhong University of Science and Technology Tongji Medical College | Bispecific antibody (Trop2/CD3) | – | Preclinical | (46) |
| Anti-Trop2/CD3 bispecific antibody | Sunshine Guojian Pharmaceutical | Bispecific antibody (Trop2/CD3) | CRD, C34-K72 | Preclinical | (47) |
| TF12 | Radboud University Medical Center | Bispecific antibody (Trop2/HSG) | – | Preclinical | (48) |